EGFR Signaling in Lung Fibrosis

Cells. 2022 Mar 14;11(6):986. doi: 10.3390/cells11060986.

Abstract

In this review article, we will first provide a brief overview of the ErbB receptor-ligand system and its importance in developmental and physiological processes. We will then review the literature regarding the role of ErbB receptors and their ligands in the maladaptive remodeling of lung tissue, with special emphasis on idiopathic pulmonary fibrosis (IPF). Here we will focus on the pathways and cellular processes contributing to epithelial-mesenchymal miscommunication seen in this pathology. We will also provide an overview of the in vivo studies addressing the efficacy of different ErbB signaling inhibitors in experimental models of lung injury and highlight how such studies may contribute to our understanding of ErbB biology in the lung. Finally, we will discuss what we learned from clinical applications of the ErbB1 signaling inhibitors in cancer in order to advance clinical trials in IPF.

Keywords: ErbB-signaling; TGF-α; TGF-β; amphiregulin; epidermal growth factor; epidermal growth factor receptor; idiopathic pulmonary fibrosis; lung fibrosis; neuregulin 1; pulmonary fibrosis; tyrosine kinase inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • ErbB Receptors / metabolism
  • Humans
  • Idiopathic Pulmonary Fibrosis* / pathology
  • Ligands
  • Lung / pathology
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Ligands
  • EGFR protein, human
  • ErbB Receptors